Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis
- PMID: 18702995
- DOI: 10.1016/S1474-4422(08)70174-1
Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis
Comment on
-
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X. Lancet Neurol. 2008. PMID: 18703004 Clinical Trial.
Similar articles
-
The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.Rheumatology (Oxford). 2018 Feb 1;57(2):246-254. doi: 10.1093/rheumatology/kex186. Rheumatology (Oxford). 2018. PMID: 28541488 Review.
-
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.Semin Cutan Med Surg. 2010 Mar;29(1):48-52. doi: 10.1016/j.sder.2010.02.001. Semin Cutan Med Surg. 2010. PMID: 20430307 Review.
-
Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.Neurodegener Dis. 2008;5(1):32-7. doi: 10.1159/000109936. Neurodegener Dis. 2008. PMID: 18075273 Review.
-
Ustekinumab poised to enter the psoriasis market.Nat Biotechnol. 2008 Dec;26(12):1317-8. doi: 10.1038/nbt1208-1317a. Nat Biotechnol. 2008. PMID: 19060851 No abstract available.
-
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X. Lancet Neurol. 2008. PMID: 18703004 Clinical Trial.
Cited by
-
Advances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis.Mediators Inflamm. 2015;2015:475158. doi: 10.1155/2015/475158. Epub 2015 Dec 7. Mediators Inflamm. 2015. PMID: 26770017 Free PMC article. Review.
-
IL12Rβ1: the cytokine receptor that we used to know.Cytokine. 2015 Feb;71(2):348-59. doi: 10.1016/j.cyto.2014.11.018. Epub 2014 Dec 13. Cytokine. 2015. PMID: 25516297 Free PMC article. Review.
-
A novel human truncated IL12rβ1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation.Oncotarget. 2015 Oct 6;6(30):28539-55. doi: 10.18632/oncotarget.5164. Oncotarget. 2015. PMID: 26384304 Free PMC article.
-
Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies.J Interferon Cytokine Res. 2012 Apr;32(4):139-51. doi: 10.1089/jir.2011.0103. Epub 2011 Dec 22. J Interferon Cytokine Res. 2012. PMID: 22191464 Free PMC article. Review.
-
Interaction between Th17 and central nervous system in multiple sclerosis.Brain Behav Immun Health. 2024 Dec 24;43:100928. doi: 10.1016/j.bbih.2024.100928. eCollection 2025 Feb. Brain Behav Immun Health. 2024. PMID: 39845807 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical